TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019)